Treatment with anti-CD25 monoclonal antibody and filtration plasmapheresis in highly sensitive kidney recipients

Objective To investigate the treatment with anti-CD25 monoclonal antibody on the basis of double filtration plasmapheresis (DFPP) in highly sensitive kidney recipients. Methods In 41 highly sensitive recipients [panel reactive antibody (PRA) 52. 2% in average),24 cases were only treated with DFPP before operations (control group) and 17 cases were treated with anti-CD25 monoclonal antibody on the basis of DFPP (treatment group). Incidence and severity of acute rejection,1-year survival rate of human/ kidney and complications were made a comparison between the two groups. Results In treatment group,2 cases (11. 8% ) were suffered from acute rejection (type IA and IIB respectively) and in control group,1 case (4. 2% ) was suffered from hyperacute rejection and 10 cases (41.7% ) were suffered from acute rejection (6 cases beyond type IIA),Which was significantly different between the two groups ( P = 0. 039). One year survival rate of human/kidney was 100% /94. 1% in treatment group and 100%/91.7% in control group. Incidence of complications was not significantly different between the two groups. Conclusions Treatment with anti-CD25 monoclonal antibody on the basis of DFPP can significantly decrease incidence and severity of acute rejection in highly sensitive kidney recipients and possess satisfactory 1-year survival rate of human/kidney.